Boston Scientific announces pricing of €1.5 billion of senior notes

Boston Scientific Corporation Boston Scientific Corporation today announced that American Medical Systems Europe B.V. ("AMS Europe"), its wholly owned finance subsidiary, has priced a public offering of €850,000,000 aggregate principal amount of 3.000% notes due 2031 and €650,000,000 aggregate principal amount of 3.250% notes due 2034 (collectively, the "Notes").

The Notes will be fully and unconditionally guaranteed by the Company. The offering is being made pursuant to a registration statement filed with the U.S. Securities and Exchange Commission.

The offering is expected to close on February 26, 2025, subject to customary closing conditions. The Company intends to use the net proceeds from the offering, together with cash on hand, to fund the repayment at maturity of AMS Europe's 0.750% senior notes due March 8, 2025 and to pay accrued and unpaid interest with respect to such notes, and for general corporate purposes, which may include, among other things, short term investments, reduction of short term debt, funding of working capital and potential future acquisitions.

About Boston Scientific

Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of health care. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions.